@entity1566 ( @entity1566 ) results in abnormal locomotor and @entity158 syndromes in @entity1 . T13 spinal hemisection in the @entity35 results in development of permanent mechanical @entity1931 and thermal @entity1931 partially due to interruption of descending inhibitory modulators such as @entity750 ( @entity750 ). We hypothesize that lumbar transplantation of nonmitotic cells that tonically secrete antinociceptive and trophic compounds will reduce the @entity158 -like behavior and enhance locomotor recovery after @entity1566 . We used RN46A-B14 cells, a conditionally immortalized (SV40tsTag) @entity35 neuronal cell line derived from E13 raphe bioengineered to secrete both @entity750 and @entity2136 in vitro at both permissive (33 degrees C) and nonpermissive (39 degrees C) temperatures. Three groups (n = 72) of 30-day-old male @entity35 were spinally hemisected at T13 and allowed 4 weeks for adequate recovery of locomotor function and development of @entity1931 and @entity1931 . Immunosuppressed animals received either lumbar RN46A-B14 (n = 24) or control RN46A-V1 (n = 24) empty-vector transplants or no cell (n = 24) transplant. HPLC analysis of media and CSF demonstrated increases of both in vitro and in vivo @entity750 levels at 28 days in RN46A-B14 animals. ELISA demonstrated @entity2136 secretion in vitro and in vivo by RNA46A-B14 cells. Locomotor function (BBB scale) and @entity146 measured by paw withdrawals to von Frey filaments, radiant heat, and noxious pin stimuli were tested for 4 weeks posttransplant. Animals receiving RN46A-B14 cells demonstrated significantly improved locomotor function and reductions in both fore- and hindlimb mechanical @entity1931 and thermal @entity1931 compared to controls receiving RN46A-V1 or no transplants. These effects were modulated by the @entity750 antagonist @entity3858 and reuptake inhibitor @entity3755 . @entity1603 and @entity750 immunoreactivity confirmed cell survival and graft location 4 weeks posttransplantation. These results support the therapeutic potential of bioengineered @entity750 -secreting cell lines in @entity1118 following @entity1566 .

Engraftment of serotonergic precursors enhances locomotor function and attenuates chronic central XXXX following spinal hemisection injury in the @entity35 .

@entity1 :: ('9606', 'Species') :: ['humans'] @entity1603 :: ('MESH:D001973', 'Chemical') :: ['Bromodeoxyuridine'] @entity2136 :: ('24225(Tax:10116)', 'Gene') :: ['BDNF'] @entity1931 :: ('MESH:D006930', 'Disease') :: ['allodynia', 'hyperalgesia'] @entity3858 :: ('MESH:D008784', 'Chemical') :: ['methysergide'] @entity35 :: ('10116', 'Species') :: ['rat', 'Sprague-Dawley rats'] @entity146 :: ('MESH:D001523', 'Disease') :: ['nociceptive behaviors'] @entity3755 :: ('MESH:D016666', 'Chemical') :: ['fluvoxamine'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain'] @entity750 :: ('MESH:D012701', 'Chemical') :: ['serotonin', '5-HT'] @entity1566 :: ('MESH:D013119', 'Disease') :: ['Spinal cord injury', 'spinal cord injury', 'SCI'] @entity1118 :: ('MESH:D059350', 'Disease') :: ['reducing chronic central pain']
@entity158 :: (MESH:D010146,Disease) :: ['pain behavior']
